The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China
Yun Zhang , Jianming Xu , Jie Shen , Shanzhi Gu , Lihua Wu , Jian Wu , Guoliang Shao , Yanqiao Zhang , Li Xu , Tao Yin , Jingfeng Liu , Zhenggang Ren , Jianping Xiong , Xianhai Mao , Ling Zhang , Jiayin Yang , Lequn Li , Xiaoming Chen , Zhiming Wang , Quanren Wang
Background: C+A combination therapy displayed high objective response rate, disease control rate, and durable response with a manageable safety profile in patients (pts) with advanced HCC. Here we performed an updated analysis of OS to characterize the OS benefit of C+A in HCC pts. Methods: 70 pts in first-line cohort and 120 pts in second-line cohort were enrolled. Median OS and 2-year OS rate were evaluated via updated data (data cutoff, 3 January, 2021). Median time from enrollment to data cutoff of the total population (N = 190) was 29.1 months (range, 24.0-33.7). Results: OS events had occurred in 58.6% pts in first-line cohort and 60.0% pts in second-line cohort. The median OS was 20.1 months (95% CI, 14.9-NR) and 2-year OS rate was 43.3% (95% CI, 31.3-54.7) in first-line cohort. The median OS was 21.8 months (95% CI, 17.3-26.8) and 2-year OS rate was 44.6% (95% CI, 35.5-53.3) in second-line cohort. Conclusions: Long-term follow-up of C+A demonstrated remarkable survival benefit in advanced HCC pts, which further suggested that C+A is a promising combination therapy in advanced HCC pts. Clinical trial information: NCT03463876
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Jiabei Wang
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Lorenza Rimassa
2023 ASCO Annual Meeting
First Author: Li Jingjing